We apologize for the slight delay in getting to other notable news from the annual meeting of the American Society for Clinical Oncology. (Other elements of the rest of life interfered.) However, here is the keypoint summary with links to the relevant abstracts: … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: ASCO, radium-223, tasquinimod, update | 5 Comments »
In an article just published in the Journal of Clinical Oncology, the American Society of Clinical Oncology (ASCO) has strongly recommended against the use of advanced imaging technologies for determining the spread of prostate cancer in men with early stage, low-risk disease. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: ASCO, Choosing Wisely, guidelines, outcome | 1 Comment »
As we get closer to the annual meeting of the American Society of Clinical Oncology (ASCO) — to be held at the beginning of June — the investor community is beginning its annual frenzy of speculation about exactly what new information will be presented at the meeting about development stage and marketed drugs. … READ MORE …
Filed under: Drugs in development | Tagged: abiraterone, ASCO, investment, MDV3100 | 1 Comment »
There were about 50 prostate cancer-specific posters presented in the general poster session on Sunday, and we will give a quick overview of some of the more interesting ones. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: ASCO, CRPC, neoadjuvant chemotherapy | Leave a comment »
The following report provide links to a second group of abstracts of papers on prostate cancer given in the abstract listings for the annual meeting of the American Society for Clinical Oncology (ASCO) as “publication only” abstracts but which will not actually be presented at the meeting: … READ MORE …
Filed under: Uncategorized | Tagged: 2009, abstracts, ASCO | Leave a comment »
The following report gives core information on a sixth and final group of prostate cancer papers that are being formally presented at ASCO. … READ MORE …
Filed under: Uncategorized | Tagged: 2009, abstracts, ASCO | Leave a comment »
The following report gives core information on a fifth group of 15 papers that are being formally presented at ASCO. … READ MORE …
Filed under: Uncategorized | Tagged: 2009, abstracts, ASCO | Leave a comment »
The following report gives core information on a fourth group of 15 papers that are being formally presented at ASCO. … READ MORE …
Filed under: Uncategorized | Tagged: 2009, abstracts, ASCO | Leave a comment »
The following abstracts of papers on prostate cancer are given in the abstract listings for the annual meeting of the American Society for Clinical Oncology (ASCO) as “publication only” abstracts but will not actually be presented at the meeting: … READ MORE …
Filed under: Uncategorized | Tagged: 2009, abstracts, ASCO | 2 Comments »
Over the next few days we plan to work our way through the abstracts for the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) , which were made available on line yesterday, and let you know what studies look to be of interest. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Prevention, Risk, Treatment | Tagged: abstracts, annual meeting, ASCO | Leave a comment »
The annual meeting of the American Association for Cancer Research starts tomorrow in Denver, Colorado. … READ MORE …
Filed under: Drugs in development, Prevention | Tagged: AACR, ASCO, finasteride | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 